{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "IDYA",
  "name": "IDEAYA Biosciences, Inc.",
  "url": "https://orbyd.app/dossiers/IDYA/",
  "json_url": "https://orbyd.app/dossiers/IDYA.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Darovasertib approval trade: OptimUM-02 registrational win (HR 0.42, PFS 6.9 vs 3.1 mo, ASCO 2026-06-01) puts a first US uveal-melanoma NDA in flight under FDA RTOR, filing guided H2 2026. Fortress balance sheet (~$973M cash Q1 + $300M June raise); stock reclaimed to ~$35.40, +31% above the $27 offering. 2026-08-04 Q2 print is the next tell.",
  "invalidation_trigger": "A weekly close below $30 loses the post-OptimUM-02 base and marks a retrace halfway toward the June $27.00 offering shelf, signaling the approval trade is being faded pre-NDA; secondary break is the darovasertib NDA slipping past its H2 2026 filing window or the oncology-immunology theme flipping to SATURATED as rival synthetic-lethality/DLL3-ADC readouts capture the bid.",
  "catalyst_date": "2026-08-04",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "m-and-a-special-situations",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "NDA under FDA OCE Real-Time Oncology Review (RTOR); first pre-submission module May 2026; filing completion guided H2 2026; fast track designation.",
    "Balance sheet: $972.9M cash/marketable securities at 2026-03-31, runway into 2030, PLUS $300M gross raise priced 2026-06-09 at $27.00 (5,555,556 shares + pre-funded warrants). Offering shelf $27.00 = distant floor, not underwater — spot ~$35.40 on 2026-07-24.",
    "Servier partnership (Aug 2025): $210M upfront + up to $320M milestones + double-digit royalties, shared darovasertib development cost. Q1 2026 collaboration revenue $6.6M (vs $10.9M Q4 2025).",
    "IDE849 (SHR-4849) DLL3-TOP1 ADC with Hengrui: positive Phase 1 in SCLC/NEC (100 pts); long-term data at ESMO 2026; first registrational trial targeted by YE2026 (China + US).",
    "ESMO 2026 (Madrid, Oct 23-27): 3 darovasertib presentations (OptimUM-02, HLA*A2-positive OptimUM-01, neoadjuvant OptimUM-09) + Hengrui IDE849.",
    "Analyst targets: RBC Outperform $48, Truist Buy $63 (both cut 2026-07-07, ratings maintained), Wedbush Outperform $58 (2026-06-12); average ~$52.29.",
    "M&A comp: GSK acquired Nuvalent $10.6B (announced 2026-06-09); IDEAYA runs an existing GSK Pol-theta partnership — takeout optionality intact.",
    "Not a retail-squeeze name; clinical-stage, event-driven. Keep fresh sizing measured into the 2026-08-04 print; treat inside-3-day pre-earnings as a hard blocker."
  ],
  "body_markdown": "## Current Thesis\nIDEAYA has crossed from \"clinical-stage story\" to \"approval trade.\" The registrational Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in first-line HLA*A2-negative metastatic uveal melanoma met its primary endpoint (HR 0.42; median PFS 6.9 vs 3.1 months; ORR 37.1% vs 5.8% with 5 complete responses), with complete data delivered in an ASCO late-breaking oral on 2026-06-01. The company began a rolling NDA under the FDA Oncology Center of Excellence Real-Time Oncology Review (RTOR) program — first pre-submission module in May, filing completion guided to H2 2026, with fast track designation. This is the leg an investor buys: a de-risked pivotal readout feeding a rolling submission toward the first US approval in an indication with no approved 1L standard for HLA*A2-negative patients. The balance sheet removes the classic biotech tail risk — $972.9M cash at 2026-03-31 (runway into 2030), topped up by a $300M raise on 2026-06-09. Price has reclaimed to ~$35.40 (2026-07-24), roughly 31% above the $27.00 offering, so the June deal financed strength, not a rescue. The nearest tell is the 2026-08-04 Q2 print, where NDA filing timing gets updated.\n\n## Bull Case\n- OptimUM-02 primary endpoint hit hard: HR 0.42, median PFS 6.9 vs 3.1 months, ORR 37.1% vs 5.8%, 5 complete responses in the darovasertib+crizotinib arm — complete data at ASCO 2026-06-01. The largest binary in the story is already behind the tape.\n- Regulatory path is short and expedited: rolling NDA under FDA RTOR, first pre-submission module May 2026, completion guided H2 2026, fast track designation — a structure that can compress the gap from filing to decision versus a standard review.\n- Fortress balance sheet: $972.9M cash/marketable securities at 2026-03-31 with runway guided into 2030, plus the $300M gross raise priced 2026-06-09 (5,555,556 shares + pre-funded warrants at $27.00). Financing overhang that dominated the June narrative is now cleared for years.\n- Non-dilutive validation from Servier (partnership signed Aug 2025): $210M upfront, up to $320M in milestones, double-digit royalties, and shared development cost on darovasertib — a large-pharma partner underwriting the ex-US build-out.\n- Second pipeline pillar maturing: IDE849 (SHR-4849), a DLL3-TOP1 ADC partnered with Hengrui, posted positive Phase 1 data in small-cell lung and neuroendocrine carcinomas (100 patients), with long-term data due at ESMO 2026 and a first registrational trial targeted to start by year-end 2026 — leverage to the same DLL3-ADC wave that re-rated the space.\n- Takeout optionality is live: GSK's $10.6B acquisition of Nuvalent (announced 2026-06-09) confirms big-pharma appetite for near-approval precision oncology, and IDEAYA already runs a GSK Pol-theta collaboration.\n- Street still frames wide upside even after the 2026-07-07 target cuts: RBC $48, Truist $63, Wedbush $58 (2026-06-12), average near $52.29 — roughly 47% above spot.\n\n## Bear Case\n- The easy de-risking is done. With OptimUM-02 positive and the raise absorbed, the remaining catalysts (NDA acceptance, label, HLA*A2-positive OptimUM-01 data) are incremental relative to the pivotal readout that already re-rated the stock off $27.\n- Analyst revisions still point down: both RBC and Truist cut targets on 2026-07-07 while maintaining ratings — the direction of estimate travel is lower even as the headline path improved.\n- Uveal melanoma is a small addressable market; the commercial ceiling on a first approval is modest until neoadjuvant (OptimUM-09) and HLA*A2-positive expansions read out and convert.\n- RTOR is expedited but not guaranteed — a rolling submission can stall on CMC, data-package, or review-division questions, and \"H2 2026 filing\" is a window, not a fixed date the tape can grade.\n- The DLL3-ADC field IDE849 targets is crowded (tarlatamab established, Zai Lab and others active); Phase 1 promise must survive registrational scrutiny.\n- Pre-revenue economics: darovasertib collaboration revenue was $6.6M in Q1 2026 (down from $10.9M in Q4 2025); the equity is valued on forward approvals, so any RTOR slip compresses the multiple fast.\n\n## Setup & Price Structure\nThe reference shelf is the 2026-06-09 offering at $27.00; the stock has since built above it, printing ~$37.66 on 2026-07-02 before easing to ~$35.40 by 2026-07-24 — a consolidation that holds the post-data breakout rather than a fresh vertical leg. That behavior reframes the level map: the $27.00 shelf is no longer a \"participants underwater\" risk but a distant floor roughly 24% below spot. The working structure is a base in the low-to-mid $30s digesting the OptimUM-02 pop, with the July high near $37.66 as the shelf to reclaim for the next leg and the round $30 area as the line that separates \"healthy consolidation\" from \"approval trade being faded.\" A fresh entry here is buying a constructive base into an expedited regulatory path, not chasing an extended breakout. The wide gap to Street targets ($48–63) is upside only if NDA progress and H2 data updates re-rate it; on a clinical-stage name that gap is a payoff profile, not a valuation cushion. Q2 earnings on 2026-08-04 sits about seven trading sessions out — close enough to keep fresh sizing measured, not yet inside a hard binary-risk blackout.\n\n## Catalyst Calendar (next 30 days)\n\n- H2 2026 (window, ongoing): completion of the rolling darovasertib NDA under FDA RTOR — the defining event for the approval trade; incremental module color can leak through the Q2 call.\n- Beyond 30d, on the radar — 2026-10-23 to 2026-10-27 (ESMO, Madrid): three darovasertib presentations (OptimUM-02, HLA*A2-positive OptimUM-01, neoadjuvant OptimUM-09) plus Hengrui's long-term IDE849 Phase 1 data in SCLC/NEC.\n- Beyond 30d — H2 2026: targeted clinical data update for the darovasertib combination in HLA*A2-positive mUM (OptimUM-01) and initiation of the first IDE849 registrational trial by year-end.\n\n## Elapsed catalysts\n\n- 2026-08-04: Q2 2026 earnings and business update — the near-term tell. Watch for confirmation of NDA filing timing (H2 2026), RTOR module cadence, and cash-runway reiteration into 2030. *(passed 5d ago)*\n\n## What Would Change Our Mind\nThe thesis breaks on a weekly close below $30, which loses the post-OptimUM-02 base and marks a retrace halfway back toward the June $27.00 offering shelf — the signal that the approval trade is being distributed ahead of, not into, the NDA. A secondary invalidation is a regulatory stumble: the darovasertib NDA slipping past its H2 2026 filing window, an FDA refuse-to-file, or a CMC/clinical hold that converts the RTOR shortcut into a standard-review timeline. The third condition is thematic — the oncology-immunology and precision-biotech complex flipping to SATURATED as competing synthetic-lethality and DLL3-ADC readouts capture the takeout bid and the incremental capital, leaving IDEAYA a single-approval story with a small near-term market. Absent those, consolidation above $30 with the NDA advancing keeps the base intact.\n\n## Correlation Notes\n- Sector beta: trades with XBI and the small/mid-cap biotech complex; rate-sensitive, so a tightening macro regime or a risk-off leg in speculative biotech pressures the multiple independent of pipeline progress.\n- Partner-linked exposure: darovasertib economics are shared with Servier (ex-US) and IDE849 with Hengrui — partner pipeline decisions and China-regulatory headlines feed back into the sum-of-parts.\n- Idiosyncratic core: uveal-melanoma approval risk is largely single-name and event-driven; the stock decouples from the index around OptimUM/NDA milestones and RTOR headlines more than around broad tape.\n- M&A read-through: precision-oncology takeouts (GSK/Nuvalent $10.6B, 2026-06-09) set the comp for takeout optionality; a fresh large-cap acquisition in synthetic lethality or DLL3-ADC would re-rate the whole cohort, including IDYA.\n- Theme cohort: moves loosely with other de-risked, near-approval oncology names and the DLL3-ADC group (tarlatamab-adjacent), where a positive peer readout lifts sentiment and a peer failure drains the takeout premium.",
  "first_seen": "2026-07-07",
  "last_analyzed": "2026-07-26T12:22:51+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}